178 related articles for article (PubMed ID: 24666307)
21. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV
Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A).
Africander DJ; Storbeck KH; Hapgood JP
J Steroid Biochem Mol Biol; 2014 Sep; 143():404-15. PubMed ID: 24861265
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of progestins used in hormonal contraception and progesterone via the progesterone receptor.
Enfield K; Cartwright M; Toit RL; Avenant C; Africander D; Hapgood JP
Biochem Biophys Res Commun; 2020 Dec; 533(4):879-885. PubMed ID: 33008590
[TBL] [Abstract][Full Text] [Related]
24. In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties.
Afhüppe W; Beekman JM; Otto C; Korr D; Hoffmann J; Fuhrmann U; Möller C
J Steroid Biochem Mol Biol; 2010 Mar; 119(1-2):45-55. PubMed ID: 20043998
[TBL] [Abstract][Full Text] [Related]
25. Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer.
Teulings FA; van Gilse HA; Henkelman MS; Portengen H; Alexieva-Figusch J
Cancer Res; 1980 Jul; 40(7):2557-61. PubMed ID: 6248208
[TBL] [Abstract][Full Text] [Related]
26. Non-steroidal progesterone receptor specific ligands.
Allan GF; Sui Z
Mini Rev Med Chem; 2005 Aug; 5(8):701-8. PubMed ID: 16101406
[TBL] [Abstract][Full Text] [Related]
27. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
[TBL] [Abstract][Full Text] [Related]
28. The structure and function of progesterone receptors in breast cancer.
Horwitz KB
J Steroid Biochem; 1987; 27(1-3):447-57. PubMed ID: 3320537
[TBL] [Abstract][Full Text] [Related]
29. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
30. Fluorinated androgens and progestins: molecular probes for androgen and progesterone receptors with potential use in positron emission tomography.
Brandes SJ; Katzenellenbogen JA
Mol Pharmacol; 1987 Sep; 32(3):391-403. PubMed ID: 3499564
[TBL] [Abstract][Full Text] [Related]
31. Identification and characterization of novel estrogen receptor-beta-sparing antiprogestins.
Sathya G; Jansen MS; Nagel SC; Cook CE; McDonnell DP
Endocrinology; 2002 Aug; 143(8):3071-82. PubMed ID: 12130573
[TBL] [Abstract][Full Text] [Related]
32. Effects of D-ring substituents on antiprogestational (antagonist) and progestational (agonist) activity of 11 beta-aryl steroids.
Cook CE; Lee YW; Wani MC; Fail PA; Petrow V
Hum Reprod; 1994 Jun; 9 Suppl 1():32-9. PubMed ID: 7962467
[TBL] [Abstract][Full Text] [Related]
33. The other side of progestins: effects in the brain.
Giatti S; Melcangi RC; Pesaresi M
J Mol Endocrinol; 2016 Aug; 57(2):R109-26. PubMed ID: 27339142
[TBL] [Abstract][Full Text] [Related]
34. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
35. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?
Horwitz KB
Endocr Rev; 1992 May; 13(2):146-63. PubMed ID: 1618161
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.
Nahleh Z
Future Oncol; 2008 Feb; 4(1):15-21. PubMed ID: 18240997
[TBL] [Abstract][Full Text] [Related]
37. Modulation of lactogenic receptors by progestins in cultured human breast cancer cells.
Murphy LJ; Murphy LC; Stead B; Sutherland RL; Lazarus L
J Clin Endocrinol Metab; 1986 Feb; 62(2):280-7. PubMed ID: 3001123
[TBL] [Abstract][Full Text] [Related]
38. The progesterone receptor. Biological effects of progestins and antiprogestins.
Savouret JF; Chauchereau A; Misrahi M; Lescop P; Mantel A; Bailly A; Milgrom E
Hum Reprod; 1994 Jun; 9 Suppl 1():7-11. PubMed ID: 7962473
[TBL] [Abstract][Full Text] [Related]
39. Exogenous progestagens and the human breast.
Sitruk-Ware R; Plu-Bureau G
Maturitas; 2004 Sep; 49(1):58-66. PubMed ID: 15351097
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells.
Daniel AR; Faivre EJ; Lange CA
Mol Endocrinol; 2007 Dec; 21(12):2890-906. PubMed ID: 17717077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
